(Total Views: 412)
Posted On: 03/14/2020 11:03:52 AM
Post# of 145254
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
One PR has been deleted from the website.
VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA recommended that the Company request a preliminary Breakthrough Therapy designation meeting. Meanwhile, the Company continues reporting very positive data for its mTNBC and MBC patients.
Why was it deleted?
VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
![](/m/images/icons/icon_wink.gif)
Why was it deleted?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)